Bengal Physician Journal

Register      Login

VOLUME 10 , ISSUE 3 ( September-December, 2023 ) > List of Articles

Original Article

Possible Synergism between Ampicillin and Some Pain-reducing Drugs against Escherichia coli

Thoraa Abdul Amir Drees, Falah Hasan Obayes AL-Khikani, Haider Hussein Yas Khudair, Haider Abdul Hussein Nuri, Ali Amer Hussein

Keywords : Ampicillin, Escherichia coli, Dexamethasone, Diclofenac sodium, Flagyl, Paracetamol, Synergism

Citation Information : Drees TA, AL-Khikani FH, Khudair HH, Nuri HA, Hussein AA. Possible Synergism between Ampicillin and Some Pain-reducing Drugs against Escherichia coli. Bengal Physician Journal 2023; 10 (3):79-82.

DOI: 10.5005/jp-journals-10070-8020

License: CC BY-NC 4.0

Published Online: 21-12-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Abstract

Background: Escherichia coli (E. coli) is one of the most common human bacterial pathogens implicated in antibiotic resistance, especially in the last decades. The antimicrobial combination is important to reduce these resistances. So the aim of this study is finding a possible synergism between ampicillin and other drugs to treat E. coli infections. Materials and methods: The present study was conducted for the period from January 2023 to March 2023 on bacteria E. coli. The tested bacteria isolated and identified by using standard bacteriological methods. Detection antibiotic sensitivity pattern of isolates was determined by agar well diffusion method. The antibiotics (flagyl, paracetamol, dexamethasone, diclofenac sodium, and ampicillin) were added separately in one dish, and then added in another dish combined with the ampicillin to know the effect of antibiotics on the growth of bacteria before and after the addition of ampicillin. Results: Twenty E. coli were isolated from various body sites. The study showed that females were more infected (70%) with E. coli than males (30%). Flagyl, paracetamol, and dexamethasone were resistant to all isolates (100%). But diclofenac sodium was resistant to 85% isolates. Resistance to ampicillin was 50%. Ampicillin showed synergy after combination with other agents but still nonsignificant (p > 0.05). The addition of flagyl increased the effect of ampicillin to 15.35 mm while it was 13.75 mm before the combination (p = 0.53). The addition of paracetamol increased the effect of ampicillin to 15 mm while it was 13.75 mm before the combination (p = 0.63). The addition of dexamethasone increased the effect of ampicillin to 15.55 mm, it was 13.75 mm before addition (p = 0.51). The combination of diclofenac increased the effect of ampicillin to 14.95 mm, it was 13.75 mm before addition (p = 0.64). Conclusion: Flagyl, paracetamol, and dexamethasone were resistant to all isolates (100%). But diclofenac sodium was resistant in 85% of all isolates. Ampicillin showed synergy after adding other agents but still non-significant (p > 0.05).


HTML PDF Share
  1. Braz VS, Melchior K, Moreira CG. Escherichia coli as a multifaceted pathogenic and versatile bacterium. Front Cell Infect Microbiol 2020;10:548492. DOI: 10.3389/fcimb.2020.548492.
  2. AL-Khikani F. Factors affecting flowering of Pseudomonas aeruginosa in urine. Microbes Infect Dis 2022;3(4):956–957.
  3. AL-Khikani F. Virulence factors in Pseudomonas aeruginosa: The arms race between bacteria and humans. Microbes Infect Dis 2021;4:24. DOI: 10.21608/MID.2021.99954.1202.
  4. Flores-Mireles AL, Walker JN, Caparon M, et al. Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol 2015;13(5):269–284. DOI: 10.1038/nrmicro3432.
  5. Doesschate T, Kuiper S, van Nieuwkoop C, et al. Fosfomycin vs ciprofloxacin as oral step-down treatment for Escherichia coli febrile urinary tract infections in women: A randomized, placebo-controlled, double-blind, multicenter trial. Clin Infect Dis 2022;75(2):221–229. DOI: 10.1093/cid/ciab934.
  6. AL-Khikani FH, Ayit AS. Pseudomonas aeruginosa a tenacious uropathogen: Increasing challenges and few solutions. BBRJ 2022;6(3):311. DOI: 10.4103/bbrj.bbrj_256_21.
  7. Al-Khikani FH, Kadem BJ. Unusual false-negative serum human chorionic gonadotropin detected by qualitative immunoassay: A case report of two Iraqi women. J Med Sci Res 2020;3(3):238. DOI: 10.4103/JMISR.JMISR_30_20.
  8. Salas-Herrera IG, Pearson RM, Johnston A, et al. Concentration of metronidazole in cervical mucus and serum after single and repeated oral doses. J Antimicrobial Chemotherapy 1999;28(2):283–289. DOI: 10.1093/jac/28.2.283.
  9. Kakodkar PS. Routine use of dexamethasone for postoperative nausea and vomiting: The case for. Anaesthesia 2013;68(9):889–891. DOI: 10.1111/anae.12308.
  10. Barzegar-Jalali M, Alaei-Beirami M, Javadzadeh Y, et al. Comparison of physicochemical characteristics and drug release of diclofenac sodium–eudragit RS100 nanoparticles and solid dispersions. Powder Technol 2012;219:211–216. DOI: 10.1016/j.powtec.2011.12.046.
  11. McMurtry RJ, Snodgrass WR, Mitchell JR. Renal necrosis, glutathione depletion, and covalent binding after acetaminophen. Toxicol Appl Pharmacol 1978;46(1):87–100. DOI: 10.1016/0041-008x(78)90139-4.
  12. Al-Janabi AA, Al-Khikani FH. Prophylaxis and therapeutic ability of inactivated dermatophytic vaccine against dermatophytosis in the rabbits as an animal model. Turk J Pharm Sci 2021;18(3):326. DOI: 10.4274/tjps.galenos.2020.81226.
  13. AL-Khikani FH, Ayit AS. Correlation study between urinary tract bacterial infection and some acute inflammatory responses. BBRJ 2019;3(4):236. DOI: 10.4103/bbrj.bbrj_122_19.
  14. Alhusayni AA, Al-Khikani FH, Aljaburi HK, et al. Antibiotic susceptibility profile of bacterial uropathogens in Al-Shomali General Hospital, Babylon, Iraq. Journal of Preventive, Diagnostic and Treatment Strategies in Medicine 2022;1:240. DOI: 10.4103/jpdtsm.jpdtsm_45_22.
  15. AL-Khikani FH, Kadim BJ, Ayit AS, et al. Evaluation cephalosporins resistance in pathogenic bacteria isolated clinically. World News Nat Sci 2020;31:65. DOI: 10.4103/jpdtsm.jpdtsm_376_20.
  16. Bell JM, Turnidge JD, Gales AC, et al. Prevalence of extended spectrum beta-lactamase (ESBL) - producing clinical isolates in the Asia-Pacific region and South Africa: Regional results from SENTRY Antimicrobial Surveillance Program (1998–99). Diagn Microbiol Infect Dis 2002;42(3):193–198. DOI: 10.1016/s0732-8893(01)00353-4.
  17. AL-Khikani FH, Kadim MM. Secondary unculturable bacteria associated with Sars-Cov-2: More information are required. Med J Dr DY Patil Univ 2022;15(7):S136–S137. DOI: 10.4103/mjdrdypu.mjdrdypu_698_21.
  18. Mohiuddin AK. UTI prevalence among population with chronic conditions. J Med Res Case Rep 2019;1(2):89.
  19. Ebie MY, Kandakai-Olukemi YT, Ayanbadejo J, et al. Urinary tract infections in a Nigerian military hospital. Nigerian J Microbiol 2001; 15(1):31–37.
  20. Leitner L, Sybesma W, Chanishvili N, et al. Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo-controlled, double-blind clinical trial. BMC Urol 2017;17:1–6. DOI: 10.1186/s12894-017-0283-6.
  21. Al-Khikani FH, Almosawey HA, Abdullah YJ, et al. Potential antiviral properties of antifungal drugs. J Egypt Women Dermatol Soc 2020;17:185. DOI: 10.4103/JEWD.JEWD_40_20.
  22. AL-Khikani FH. Pulmonary mycoses treated by topical amphotericin B. BBRJ. 2020;4(2):123. DOI: 10.4103/bbrj.bbrj_12_20.
  23. Obayes AK, Hasan F. The forgotten role of methenamine to prevent recurrent urinary tract infection: Urgency for reuse 100 years after discovery. Pharmaceut Biomed Res 2020;6(4):247–250. Available from: http://dx.doi.org/10.18502/pbr.v6i4.5110.
  24. Staji H, Rassouli M, Jourablou S. Comparative virulotyping and phylogenomics of Escherichia coli isolates from urine samples of men and women suffering urinary tract infections. Iranian journal of basic medical sciences 2019;22(2):211. DOI: 10.22038/ijbms.2018.28360.6880.
  25. Naqid IA, Hussein NR, Balatay A, et al. Antibiotic susceptibility patterns of uropathogens isolated from female patients with urinary tract infection in Duhok province, Iraq. Jundishapur J Health Sci 2020;12(3):76. DOI: 10.5812/jjhs.105146.
  26. Mansour Amin, Zohreh Pourdangchi. Study of bacteria isolated from urinary tract infections and determination of their susceptibility to antibiotics. Jundishapur Journal of Microbiology 2009;7:118–123.
  27. Xu C, Kong L, Liao Y, et al. Mini-review: Antibiotic-resistant Escherichia coli from farm animal-associated sources. Antibiotics 2022;11(11):1535. DOI: 10.3390/antibiotics11111535.
  28. Krishna A, Zere T, Mistry S, et al. Evaluation of a sequential antibiotic treatment regimen of ampicillin, ciprofloxacin and fosfomycin against Escherichia coli CFT073 in the hollow fiber infection model compared with simultaneous combination treatment. Antibiotics 2022;11(12):1705. DOI: 10.3390/antibiotics11121705.
  29. AL-Khikani FH. Antimicrobial resistance profile among major bacterial pathogens in Southern Babil, Iraq. Galician Med J 2020;27(3):20. DOI: 10.21802/gmj.2020.3.6.
  30. Al-Khikani F, Ayit A. The antibacterial action of safranin and gentian violet. Rambam Maimonides Med J 2022;13:76. DOI: 10.5041/RMMJ.10475.
  31. AL-Khikani FH. Non culturable bacteria associated with COVID-19: More details are demanded. Microb Infect Dis 2021;2:611–612. DOI: 10.21608/MID.2021.92689.1186.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.